Physician profile
Amit Verma
NPI 1619958873
$493,093.33
in general payments reported to CMS, 2019-2025
40 companies · $22K in 2025
The $22K reported for 2025 was more than what 94% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100K · 2020: $86K · 2021: $73K · 2022: $93K · 2023: $83K · 2024: $36K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Honoraria: $54K · Travel and Lodging: $18K · Food and Beverage: $8,223 · Consulting Fee: $4,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,109.00 |
| Honoraria | $54,050.00 |
| Travel and Lodging | $18,449.71 |
| Food and Beverage | $8,223.16 |
| Consulting Fee | $4,410.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $144,474.70 | 2020-2025 | Xcopri |
| Neurelis, INC. | $123,487.43 | 2020-2025 | Valtoco |
| Eisai INC. | $96,667.60 | 2019-2022 | |
| Ucb, INC. | $40,397.24 | 2019-2025 | Nayzilam, Fintepla, Briviact |
| Sunovion Pharmaceuticals INC. | $29,671.03 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $19,521.39 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $14,813.48 | 2023-2024 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $13,981.11 | 2023-2025 | Fycompa |
| Takeda Pharmaceuticals U.S.A., INC. | $3,630.00 | 2020 | |
| Otter Pharmaceuticals, LLC | $1,482.25 | 2024-2025 | Sympazan |
| Ucb Sa | $1,407.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $1,033.46 | 2022-2025 | |
| Zogenix INC. | $489.15 | 2021 | |
| Monteris Medical Corporation | $473.77 | 2020-2025 | Neuroblate |
| Greenwich Biosciences, INC. | $397.77 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aucta Pharmaceuticals, INC. | $153.88 | 2024-2025 | Motpoly Xr |
| Amneal Pharmaceuticals LLC | $153.36 | 2023-2024 | Crexont |
| Neuropace, INC. | $131.11 | 2020 | |
| Immedica Pharma US, INC. | $130.84 | 2023 | |
| Livanova USA, INC. | $72.63 | 2021 | |
| Supernus Pharmaceuticals, INC. | $71.18 | 2019-2020 | |
| Ceribell, INC. | $40.74 | 2024 | Pocket Eeg Device |
| Amylyx Pharmaceuticals, INC. | $40.24 | 2023 | Relyvrio |
| Csl Behring | $38.22 | 2019-2022 | |
| Abbvie INC. | $35.02 | 2021-2023 | Botox |
| Biogen, INC. | $34.75 | 2021-2023 | Tysabri, Vumerity |
| Amgen INC. | $33.88 | 2019 | |
| Ge Healthcare | $31.73 | 2023 | |
| Springworks Therapeutics, INC. | $26.62 | 2025 | Gomekli |
| Bausch Health US, LLC | $24.71 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.62 | 2022 | |
| Grt US Holding, INC. | $17.08 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.00 | 2023 | Xarelto |
| Genentech USA, INC. | $15.76 | 2025 | Ocrevus Zunovo |
| Grifols USA, LLC | $15.49 | 2019 | |
| Allergan, INC. | $15.08 | 2019 | |
| Genzyme Corporation | $15.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.60 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.